Glucokinase

A group of enzymes that catalyzes the conversion of ATP and D-glucose to ADP and D-glucose 6-phosphate. They are found in invertebrates and microorganisms, and are highly specific for glucose. (Enzyme Nomenclature, 1992) EC 2.7.1.2.

Also Known As:

Networked: 628 relevant articles (8 outcomes, 62 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Ellard, Sian: 20 articles (07/2015 - 09/2003)
2.	Hattersley, Andrew T: 16 articles (07/2015 - 09/2003)
3.	Gloyn, Anna L: 16 articles (07/2015 - 09/2003)
4.	Matschinsky, Franz M: 15 articles (02/2013 - 04/2002)
5.	Hattersley, A T: 11 articles (11/2007 - 01/2000)
6.	Pfefferkorn, Jeffrey A: 9 articles (02/2015 - 02/2012)
7.	Grimsby, Joseph: 9 articles (08/2012 - 01/2006)
8.	Owen, Katharine R: 8 articles (12/2014 - 02/2010)
9.	Ellard, S: 8 articles (08/2013 - 02/2000)
10.	Hansen, Torben: 7 articles (08/2014 - 04/2002)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 10/01/1992 - "The discovery that glucokinase mutations can cause MODY and was also found in ten affected members of a pedigree with type 2 diabetes in which MODY had not previously been considered indicates that diagnosis based on molecular pathology will be helpful in understanding the aetiology of type 2 diabetes." 10/01/2013 - "Our study aims were to determine the frequency of MODY mutations (HNF1A, HNF4A, glucokinase) in a diverse population of youth with diabetes and to assess how well clinical features identify youth with maturity-onset diabetes of the young (MODY). " 10/01/2013 - "Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus." 02/01/2013 - "A proof of concept study was conducted to investigate the safety and tolerability of a novel oral glucokinase activator, LY2599506, during multiple dose administration to healthy volunteers and subjects with Type 2 diabetes mellitus (T2DM). " 04/01/2010 - "The aim of this study was to determine whether or not mutations in the 3 commonest forms of MODY, hepatic nuclear factor 4α (HNF4α), HNF1α and glucokinase (GK), are a cause of diabetes in young Omanis. "
2.	Insulinoma 02/25/1983 - "Kinetic studies of insulinoma glucokinase also indicated similarity with liver glucokinase, i.e. " 05/01/2008 - "Non-insulinoma persistent hyperinsulinaemic hypoglycaemia caused by an activating glucokinase mutation: hypoglycaemia unawareness and attacks." 11/15/1996 - "Reporter plasmids with the liver glucokinase promoter and any length of flanking sequence were minimally active in INS-1 insulinoma cells, and conversely reporters with the beta-cell-specific promoter were ineffective in primary hepatocytes. " 10/01/1992 - "Multiple elements in the upstream glucokinase promoter contribute to transcription in insulinoma cells." 07/01/1988 - "Characteristics of glucokinase of the Kirkman insulinoma."
3.	Hypoglycemia (Reactive Hypoglycemia) 04/01/2014 - "Glucokinase activators (GKAs), such as AZD1656, are designed as antihyperglycemic agents for diabetics and can cause dose-limiting hypoglycemia in normal animals used in embryofetal development studies. " 02/01/2013 - "Selecting dosing regimens for phase 2 studies for a novel glucokinase activator LY2599506 is challenging due to the difficulty in modeling and assessing hypoglycemia risk. " 04/01/2002 - "In this study, a second case of hyperinsulinemic hypoglycemia due to activation of glucokinase is reported. " 09/01/2012 - "Glucokinase is expressed in the hypothalamus, but effects of glucokinase activators (GKAs) on counterregulatory responses to hypoglycemia are unknown. " 09/01/2012 - "Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy males."
4.	Diabetes Mellitus 01/01/2015 - "A new compound heterozygosis for inactivating mutations in the glucokinase gene as cause of permanent neonatal diabetes mellitus (PNDM) in double-first cousins." 12/01/2014 - "In humans, activating GCK mutations cause familial hyperinsulinaemic hypoglycaemia (GCK-HH), leading to keen interest in the potential of small-molecule glucokinase activators (GKAs) as treatments for diabetes mellitus. " 04/01/2013 - "Glucokinase (GK) is a new target for the treatment of type II diabetes mellitus (T2DM). " 01/01/2012 - "Homozygous mutations in the glucokinase gene (GCK) result in a complete deficiency of the GCK enzyme, which leads to permanent neonatal diabetes mellitus. " 01/01/2012 - "[Glucokinase gene mutation as a causative factor of permanent neonatal diabetes mellitus]."
5.	Insulin Resistance 04/01/2012 - "These findings suggest that chronic activation of glucokinase preserves beta cell mass and delays disease in the ZDF rat, a model of insulin resistance and progressive beta cell failure." 01/01/2012 - "Exendin-4-induced increase in hepatic glucokinase activity is more pronounced in the presence of hepatic insulin resistance. " 01/01/2007 - "Mice haploinsufficient for beta cell glucokinase (Gck) were unable to increase their beta cell mass in response to insulin resistance produced by high-fat feeding. " 12/01/2003 - "Moreover, we determined whether glucokinase overexpression counteracted high-fat diet-induced insulin resistance. " 12/01/2003 - "Long-term overexpression of glucokinase in the liver of transgenic mice leads to insulin resistance."

Related Drugs and Biologics

1.	Glucose (Dextrose)
2.	Insulin (Novolin)
3.	Carbon Monoxide
4.	Facilitative Glucose Transport Proteins (Glucose Transporter)
5.	Enzymes
6.	Oxidoreductases
7.	Glycogen
8.	Glyburide (Glibenclamide)
9.	Fructose
10.	Cholesterol

Related Therapies and Procedures

1.	Investigational Therapies (Experimental Therapy)
2.	Therapeutics
3.	Kidney Transplantation
4.	Transplantation (Transplant Recipients)
5.	Lasers (Laser)